Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Canaccord Genuity Sticks to Its Buy Rating for Candel Therapeutics (CADL)

Tipranks - Tipranks - Thu Oct 16, 2025

Canaccord Genuity analyst John Newman maintained a Buy rating on Candel Therapeutics yesterday and set a price target of $25.00. The company’s shares closed yesterday at $5.78.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Newman is an analyst with an average return of -0.9% and a 38.38% success rate. Newman covers the Healthcare sector, focusing on stocks such as Delcath Systems, Regeneron, and Arcellx Inc.

Candel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.00, implying a 246.32% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $23.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $14.60 and a one-year low of $3.79. Currently, Candel Therapeutics has an average volume of 786K.

Read More on CADL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).